Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)

NCT02717884 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions

DRUG: tranylcypromine
DRUG: all-trans retinoic acid
DRUG: cytarabine

Sponsor

Michael Luebbert

Collaborators

[object Object]